Literature DB >> 30767178

Postoperative Adjuvant Transarterial Chemoembolization Improves Outcomes of Hepatocellular Carcinoma Associated with Hepatic Vein Invasion: A Propensity Score Matching Analysis.

Xiu-Ping Zhang1, Yan-Chen Liu1,2, Zhen-Hua Chen1, Ju-Xian Sun1, Kang Wang1, Zong-Tao Chai1, Jie Shi1, Wei-Xing Guo1, Meng-Chao Wu1, Wan Yee Lau1,3, Shu-Qun Cheng4.   

Abstract

BACKGROUND: Vascular invasion is a major determinant of survival outcomes after curative resection for hepatocellular carcinoma (HCC) patients. This study was designed to investigate the efficacy of postoperative adjuvant transarterial chemoembolization (PA-TACE) in patients with HCC with hepatic vein tumor thrombus (HVTT).
METHODS: Data from patients who underwent LR for HCC with HVTT at the Eastern Hepatobiliary Surgery Hospital were retrospectively analyzed. The survival outcomes for patients who underwent PA-TACE after LR were compared with those who underwent LR alone. Propensity score matching (PSM) analysis was performed to match patients in a ratio of 1:1.
RESULTS: All included 319 patients who underwent LR for HCC with HVTT, 134 underwent LR alone (the LR group), and 185 patients underwent in adjuvant TACE (the PA-TACE group). PSM matched 107 patients in two groups. The overall survival (OS) and recurrence-free survival (RFS) were significantly better for patients in the PA-TACE group than the LR group (for OS: before PSM, P < 0.001; after PSM, P = 0.004; for RFS: before PSM, P < 0.001; after PSM, P = 0.013), respectively. On subgroup analysis, equivalent acceptable results were obtained in patients with peripheral HVTT (pHVTT) and major HVTT (mHVTT). However, PA-TACE resulted in no survival benefits for patients when the HVTT had extended to the inferior vena cava (IVCTT).
CONCLUSIONS: PA-TACE was associated with significantly better survival outcomes than LR alone for patients with HCC and HVTT (pHVTT and mHVTT). There was no survival benefits in patients whose HVTT had extended to form IVCTT.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30767178     DOI: 10.1245/s10434-019-07223-z

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  13 in total

Review 1.  Adjuvant treatment strategy after curative resection for hepatocellular carcinoma.

Authors:  Wei Zhang; Bixiang Zhang; Xiao-Ping Chen
Journal:  Front Med       Date:  2021-03-23       Impact factor: 4.592

2.  A new classification for hepatocellular carcinoma with hepatic vein tumor thrombus.

Authors:  Zhen-Hua Chen; Kang Wang; Xiu-Ping Zhang; Jing-Kai Feng; Zong-Tao Chai; Wei-Xing Guo; Jie Shi; Meng-Chao Wu; Wan Yee Lau; Shu-Qun Cheng
Journal:  Hepatobiliary Surg Nutr       Date:  2020-12       Impact factor: 7.293

Review 3.  Interventional Management of Portal Hypertension in Cancer Patients.

Authors:  Max Kabolowsky; Lyndsey Nguyen; Brett E Fortune; Ernesto Santos; Sirish Kishore; Juan C Camacho
Journal:  Curr Oncol Rep       Date:  2022-08-12       Impact factor: 5.945

4.  Efficacy of Postoperative Adjuvant Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Patients With Microscopic Portal Vein Invasion.

Authors:  Yiwen Qiu; Yi Yang; Tao Wang; Shu Shen; Wentao Wang
Journal:  Front Oncol       Date:  2022-06-20       Impact factor: 5.738

5.  Preoperative and postoperative nomograms for predicting early recurrence of hepatocellular carcinoma without macrovascular invasion after curative resection.

Authors:  Yanfang Zhang; Xuezhong Lei; Liangliang Xu; Xiaoju Lv; Mingqing Xu; Hong Tang
Journal:  BMC Surg       Date:  2022-06-17       Impact factor: 2.030

6.  Liver resection versus intensity-modulated radiation therapy for treatment of hepatocellular carcinoma with hepatic vein tumor thrombus: a propensity score matching analysis.

Authors:  Zhen-Hua Chen; Xiu-Ping Zhang; Shuang Feng; Jing-Kai Feng; Zong-Tao Chai; Wei-Xing Guo; Jie Shi; Wan Yee Lau; Yan Meng; Shu-Qun Cheng
Journal:  Hepatobiliary Surg Nutr       Date:  2021-10       Impact factor: 8.265

7.  Pre- and Postoperative Models for Prediction of Recurrence in Non-B, Non-C Hepatocellular Carcinoma.

Authors:  Kongying Lin; Qizhen Huang; Lei Wang; Jianxing Zeng; Zongren Ding; Hongzhi Liu; Jun Fu; Pengfei Guo; Zhenwei Chen; Yongyi Zeng; Weiping Zhou; Jingfeng Liu
Journal:  Front Oncol       Date:  2021-02-18       Impact factor: 6.244

8.  Chemotherapeutic perfusion of portal vein after tumor thrombectomy and hepatectomy benefits patients with advanced hepatocellular carcinoma: A propensity score-matched survival analysis.

Authors:  Yang Gao; Peng-Xiang Wang; Jian-Wen Cheng; Yun-Fan Sun; Bo Hu; Wei Guo; Kai-Qian Zhou; Yue Yin; Yuan-Cheng Li; Jian Wang; Jun-Feng Huang; Shuang-Jian Qiu; Jian Zhou; Jia Fan; Xin-Rong Yang
Journal:  Cancer Med       Date:  2019-09-30       Impact factor: 4.452

9.  Adjuvant transarterial chemoembolization following radical resection for intrahepatic cholangiocarcinoma: A multi-center retrospective study.

Authors:  Lei Wang; Zi-Guo Lin; Qiao Ke; Jian-Ying Lou; Shu-Guo Zheng; Xin-Yu Bi; Jian-Ming Wang; Wei Guo; Fu-Yu Li; Jian Wang; Ya-Min Zheng; Jing-Dong Li; Shi Cheng; Wei-Ping Zhou; Yong-Yi Zeng
Journal:  J Cancer       Date:  2020-04-07       Impact factor: 4.207

10.  Nomogram for Predicting Long-Term Survival after Synchronous Resection for Hepatocellular Carcinoma and Inferior Vena Cava Tumor Thrombosis: A Multicenter Retrospective Study.

Authors:  Yannan Bai; Jiayi Wu; Yong Zeng; Jie Chen; Shuangjia Wang; Shi Chen; Funan Qiu; Songqiang Zhou; Shen You; Yifeng Tian; Yaodong Wang; Maolin Yan
Journal:  J Oncol       Date:  2020-04-08       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.